Prihlásiť sa Zaregistrujte sa zadarmo

1 ročný cieľ spoločnosti Aerie Pharmaceuticals Inc

Aká je hodnota metriky 1 ročný cieľ spoločnosti Aerie Pharmaceuticals Inc?

Hodnota metriky 1 ročný cieľ spoločnosti Aerie Pharmaceuticals Inc je $27 +78.16%

Aká je definícia metriky 1 ročný cieľ?

1-ročný cieľ (1-year target) je analytikmi predpokladaná cena akcie za rok od dnešného dňa.

One year target is an estimate of a stock price for a point in time equal to a year from the current date. The price level most often reflects the collective opinion of different analysts on where the stock will be trading a year from now. For an analyst to identify an individual estimate, they have to project what a company’s business will look like in a year, typically focusing on revenue and other significant factors. They also consider the willingness of investors to pay a certain price. While the average or median recommendation may be predictive and reflect the actual future value, the results are usually not extremely successful.

1 ročný cieľ spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Aerie Pharmaceuticals Inc

Čomu sa venuje spoločnosť Aerie Pharmaceuticals Inc?

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.

Firmy s metrikou 1 ročný cieľ podobnou spoločnosti Aerie Pharmaceuticals Inc



  • Hodnota metriky 1 ročný cieľ spoločnosti KraneShares Trust je $27 +7.24%
  • Hodnota metriky 1 ročný cieľ spoločnosti freenet AG je €27 +3.16%
  • Hodnota metriky 1 ročný cieľ spoločnosti MasterCraft Boat Inc je $27 +58.69%
  • Hodnota metriky 1 ročný cieľ spoločnosti NORMA SE je €27 +86.59%
  • Hodnota metriky 1 ročný cieľ spoločnosti SI-BONE Inc je $27 +79.97%
  • Hodnota metriky 1 ročný cieľ spoločnosti AXA SA je €27 -23.77%
  • Hodnota metriky 1 ročný cieľ spoločnosti Aerie Pharmaceuticals Inc je $27 +78.16%
  • Hodnota metriky 1 ročný cieľ spoločnosti Janus Henderson plc je $27 -22.69%
  • Hodnota metriky 1 ročný cieľ spoločnosti Deutsche Grundstücksauktionen AG je €27 +240.00%
  • Hodnota metriky 1 ročný cieľ spoločnosti Hilltop Inc je $27 -12.51%
  • Hodnota metriky 1 ročný cieľ spoločnosti Xperi Inc je $27 +214.45%
  • Hodnota metriky 1 ročný cieľ spoločnosti Select Medical je $27 -19.79%
  • Hodnota metriky 1 ročný cieľ spoločnosti Spirit Airlines je $27 +994.38%